Navigation Links
NHLBI awards $11 million for molecular roadmap to chronic lung diseases
Date:10/7/2009

Researchers at National Jewish Health and four other research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options. The multi-center Lung Genomics Research Consortium will use advanced genetic and molecular tools to characterize and better understand chronic obstructive pulmonary disease and pulmonary fibrosis, then share its discoveries with researchers around the world in a web-accessible data warehouse.

"Our aim is create a genetic and molecular treasure trove for the research community to redefine these lung diseases precisely and unequivocally," said David Schwartz, MD, one of the lead researchers on the project and Director of The Center for Genes, Environment and Health at National Jewish Health. "The genetic, epigenetic, transcriptional, and phenotypic data we generate will provide an unprecedented window into the origins, dynamic biological features and unique presentations of these diseases. It will allow researchers to make fundamental discoveries that help identify individuals at risk for these diseases, diagnose them earlier, and develop more effective, personalized treatments."

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. The incidence of pulmonary fibrosis has doubled over the past decade, and now kills about 40,000 Americans each year. There are few effective treatments for either disease, and both diseases are fatal.

Researchers will study tissue samples from the NHLBI Lung Tissue Research Consortium biorepository then combine the data they generate with pathobiological, clinical and radiological data already gathered for these samples. The biorepository now contains almost 1,300 well characterized tissue samples and collects about
'/>"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. NHLBI issues first US von Willebrand Disease clinical practice guidelines
2. NOAA awards funds to improve toxic algal bloom predictions in the Western Gulf of Mexico
3. International Rett Syndrome Foundation awards $2M for cutting-edge Rett syndrome research
4. Academies announce winners of 2009 Communication Awards
5. Siebel Foundation awards top UC San Diego bioengineering graduate students
6. WPI receives $1.3 million in federal awards for ongoing research in the life sciences
7. NIH announces 115 awards to encourage high-risk research and innovation
8. Duke biomedical scientists win 2 highly prized NIH Directors Awards
9. UNC scientists garner new NIH awards for high risk, transformative research
10. 2009 Lasker Awards recognize promise of stem cells -- global market could top $700 million
11. Australian filmmakers are stars of science film awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... and Gail Williams and Stockholm University's Professor Robin Room examined ... and 2002. , Their results were published in the ... Review. , The men were categorised according to ... is a marker for lower socio-economic status (SES). ...
... one-of-a-kind diamond, a unique Picasso or the switch-hitter on ... being rare has biological benefits. Professor Marla Sokolowski, a ... the 1980s discovered that a single gene affects the ... of rarity in populations of fruit flies with two ...
... Baumann, Ph.D., Assistant Investigator, and Nancy Bae, Ph.D., ... published a paper offering insight into the way ... , Published in tomorrow's issue of Molecular Cell, ... End Joining at Human Telomeric DNA Ends" employed ...
Cached Biology News:Double the death rate from cirrhosis for 'blue collar' men 2Survival of the rarest: Fruit flies shed light on the evolution of behavior 2Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, ... PA. , The presentation took place on Tuesday, June 16 and provided ... development of APX3330 for the treatment of pancreatic cancer. A copy of the ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... July 12 to take part in the first half of “Integrative Biotechnology,” an ... a partnership established in summer 2014, this course combines students from both universities ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded ... developed by the Hadassah University Hospital, Israel,s foremost medical ... (92% owned by Hadasit Bio) has completed the recruitment ... I / II clinical trial using its treatment for ...
... (NASDAQ: PRXL ), a leading global biopharmaceutical ... for the Pharmaceutical Industry in The Eighth Annual International ... honoring great performances in business.   PAREXEL was ... efficiency of clinical trials, access emerging markets, and speed ...
... have found a new way to develop straight carbon nanofibers ... for use in novel biomedical research tools, solar cells, water ... grid, and relies on ions to ensure the nanofibers are ... "This is the first time, that I know of, where ...
Cached Biology Technology:Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 2Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 3Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 3PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 5Ions control shape of nanofibers grown on clear substrate 2Ions control shape of nanofibers grown on clear substrate 3
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
Biology Products: